



*Manufacturers of Allopathic Medicines*

CIN: L24111UP1992PLC014240

REGISTERED OFFICE,

703, ASTER 7, SUPERTech EMERALD COURT, SECTOR-93A, NOIDA-201304 (U.P.)

e-mail : raymedlabs@rediffmail.com website : www.raymedlab.com

Tel. 0120-2426900, 9412700300

10<sup>th</sup> February 2017

The Manager Listing  
BSE Limited  
Phiroze Jeejeebhoy Towers  
Dalal Street, Fort  
Mumbai – 400001

***BSE Scrip Code: 531207***

**Subject: Outcome of Board Meeting pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

Dear Sir/Madam:

This is to inform you that the Board of Directors in the meeting held today, i.e. Friday 10<sup>th</sup> February, 2017, (commenced at 11:00 A.M. and concluded at 12:30 P.M.), has inter-alia approved and passed the following resolutions:

1. Unaudited Standalone Financial Results as per Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 for the quarter ended December 31, 2016.
2. Took note of the Limited Review Report as per Annexure V of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 as placed by the auditor of the company.
3. Took note of Statement of Investor Complaints/Grievances given Under Regulation 13(3) of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 for the quarter ending on December 31, 2016.

Kindly take the above information on your records.

Thanking you,

Sincerely,

**For Raymed Labs Limited**

**Ajai Goyal**  
**Whole Time Director**

**DIN: 02636418**

**R/o: 103 Emperor 1, Supertech Emerald Court**  
**Sector 93A, Noida, UP 201304**

CC: Ahmedabad Stock Exchange Limited

*Life is Precious .....and Raymed cares*

## Raymed Labs Limited

Regd. Office: 703 Aster 7, Supertech Emerald Court, Sector 93A, Noida - 201304, Uttar Pradesh, CIN: L24111UP1992PLC014240  
E-Mail: raymedlabs@rediffmail.com, Website: www.raymedlab.com, Tel: 0120-2426900, 9412700300

### Un-audited Financial Results for the Quarter Ended on December 31, 2016

PART I		Rs. in Lacs					
	Particulars	3 Months Ended	Preceding 3 Months Ended	Corresponding 3 Months in the Previous Year Ended	Year to Date Figures for Current Period Ended	Year to Date Figures for the Previous Year Ended	Previous Year Ended
		31-12-2016	30-09-2016	31-12-2015	31-12-2016	31-12-2015	31-03-2016
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
<b>1</b>	<b>Income from Operations</b>						
	(a) Net Sales / Income from Operations (Net of excise duty)	-	-	-	-	-	-
	(b) Other Operating Income	-	-	-	-	-	-
	<b>Total Income from Operations (net)</b>	-	-	-	-	-	-
<b>2</b>	<b>Expenses</b>						
	(a) Cost of materials consumed	-	-	-	-	-	-
	(b) Purchase of stock-in-trade	-	-	-	-	-	-
	Changes in inventories of finished goods,						
	(c) work-in-progress and stock-in-trade	-	-	-	-	-	-
	(d) Employee expenses & benefits	0.19	0.23	0.23	1.00	0.68	0.90
	(e) Depreciation and amortisation expense	0.22	0.22	-	0.66	-	0.89
	(f) Other expenses	0.62	0.57	0.14	1.60	1.37	1.63
	<b>Total Expenses</b>	<b>1.02</b>	<b>1.02</b>	<b>0.37</b>	<b>3.25</b>	<b>2.05</b>	<b>3.42</b>
<b>3</b>	<b>Profit/(Loss) from Operations before other Income, Finance costs and Exceptional Items (1-2)</b>	<b>-1.02</b>	<b>-1.02</b>	<b>-0.37</b>	<b>-3.25</b>	<b>-2.05</b>	<b>-3.42</b>
4	Other Income	0.30	0.30	0.54	0.90	1.62	1.92
<b>5</b>	<b>Profit/Loss from ordinary activities before finance costs and exceptional items (3+4)</b>	<b>-0.72</b>	<b>-0.72</b>	<b>0.17</b>	<b>-2.35</b>	<b>-0.43</b>	<b>-1.50</b>
6	Finance Costs	-	-	-	-	-	-
<b>7</b>	<b>Profit/Loss from ordinary activities after finance costs but before exceptional items (5-6)</b>	<b>-0.72</b>	<b>-0.72</b>	<b>0.17</b>	<b>-2.35</b>	<b>-0.43</b>	<b>-1.50</b>
8	Exceptional Items	-	-	-	2.29	-	2.25
<b>9</b>	<b>Profit/Loss from Ordinary Activities before tax (7-8)</b>	<b>-0.72</b>	<b>-0.72</b>	<b>0.17</b>	<b>-4.64</b>	<b>-0.43</b>	<b>-3.75</b>
10	Tax Expense	-	-	-	-	-	-
<b>11</b>	<b>Net Profit/ Loss from Ordinary Activities after Tax (9-10)</b>	<b>-0.72</b>	<b>-0.72</b>	<b>0.17</b>	<b>-4.64</b>	<b>-0.43</b>	<b>-3.75</b>
12	Extraordinary Item (net of tax expense)	-	-	-	-	-	-
<b>13</b>	<b>Net Profit/ Loss for the period (11-12)</b>	<b>-0.72</b>	<b>-0.72</b>	<b>0.17</b>	<b>-4.64</b>	<b>-0.43</b>	<b>-3.75</b>
17	Paid up Equity Share Capital (Face Value Rs.10/- per share)	427.35	427.35	427.35	427.35	427.35	427.35
18	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	-	-	-	-	-	-
<b>19 i</b>	<b>Earning Per Share (before extraordinary items)</b>	<b>-0.017</b>	<b>-0.017</b>	<b>0.004</b>	<b>-0.109</b>	<b>-0.010</b>	<b>-0.088</b>
<b>19 ii</b>	<b>Earning Per Share (after extraordinary items)</b>	<b>-0.017</b>	<b>-0.017</b>	<b>0.004</b>	<b>-0.109</b>	<b>-0.010</b>	<b>-0.088</b>

**Notes:**

- 1 The unaudited financial statements for the quarter ended on December 31, 2016 as reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on February 10, 2017. The information presented above is extracted from the financial statement.
- 2 EPS has been calculated in accordance with AS-20 issued by ICAI.
- 3 The Business of the Company falls under a single segment for the purpose of Accounting Standard As-17, issued by The Institute of Chartered Accountants of India.
- 4 Previous period/year figures have been regrouped/rearranged, wherever found necessary.
- 5 No investor complaints were pending in the beginning and end of the quarter ended December 2016.

**For Raymed Labs Limited**

Ajai Goyal

**Ajai Goyal**

**Whole Time Director**

**DIN: 02636418**

**Add.: 703 Aster 7, Supertech Emerald Court, Sector 93A**

**Noida - 201304, Uttar Pradesh**

Place: NOIDA

Date: 10-02-2017



# A. Kay Mehra & Co.

CHARTERED ACCOUNTANTS

114 (Basement), Mall Road, Kingsway Camp, Delhi-110009

Tel. No. : 011-42461274, 9891295255

E-mail : akmca1969@gmail.com Website : www.akmca.in

To,

The Board of Directors

**RAYMED LABS LIMITED**

## Limited review Report for the quarter ended December 31, 2016

We have reviewed the accompanying statement of unaudited financial results of **RAYMED LABS LIMITED** for the period ended December 31, 2016 except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on review Engagement (SRE) 2400, engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed or that it contains any material misstatement.

**For A Kay Mehra & Co.**

**Chartered Accountants**

(Firm Reg No. 050004C)



**CA Deepak Suneja**

**Partner**

**M.No.501957**

**Place :New Delhi**

**Date: February 10, 2017**